Skip to Content

Vectibix Approval History

  • FDA approved: Yes (First approved September 27th, 2006)
  • Brand name: Vectibix
  • Generic name: panitumumab
  • Dosage form: Injection
  • Company: Amgen
  • Treatment for: Colorectal Cancer

Vectibix (panitumumab) is a recombinant, human IgG2 kappa monoclonal antibody indicated for the treatment of patients with epidermal growth factor receptor- (EGFr) expressing metastatic colorectal cancer after disease progression on, or following fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.

Development History and FDA Approval Process for Vectibix

Sep 27, 2006Approval Vectibix Amgen - Treatment for Metastatic Colorectal Cancer
Mar 30, 2006Amgen and Abgenix Complete Biologics License Application for FDA Approval of Panitumumab

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.